Patients, methods, and results
We used the electronic database of prescriptions of Allgemeine Ortskrankenkasse, Baden-Württemberg. This health insurer covers more than four million people, 42% of the total population of the state. We retrospectively reviewed 1.74 million anonymous prescriptions written by 6886 office based doctorsspecialists in paediatric, general, or internal medicinebetween 1 January and 31 March 1999 for 455 661 patients aged 0-16 years.
Each prescription was represented by a numerical code, describing the drug's brand name, generic name, formulation, and content per dose unit. Our database did not contain diagnoses, dosage recommendations, or individually prepared drug formulations.
To assess the licence status of prescriptions we used the summary of product characteristics (Fach information) or drug lists provided by German pharmaceutical manufacturers' associations (Gelbe Liste or Rote Liste).
We categorised prescriptions by age group and the World Health Organization's anatomical, therapeutic, and chemical classification. A prescription was considered off label if the drug itself, its dose unit, or its formulation was not explicitly covered by documentation for the specific age group to which it was prescribed. Unlicensed drugs are not specified in the database because they are not automatically reimbursed by insurance.
Of 1740 238 prescriptions, 115 366 (6.6%) prescriptions for medical accessories, diets, and cosmetics and 32 866 with unidentifiable codes were excluded; the prescriptions with unidentifiable codes might have included an unknown number of unlicensed prescriptions but accounted for only 1.9% of the database.
Among the remaining 1 592 006 prescriptions for 10 452 different active ingredients, we found 210 528 (13.2%, 95% confidence interval 13.2% to 13.3%) off label prescriptions. The table shows the most common examples and some of the associated risks.
Three quarters of off label prescriptions (157 951) resulted from lack of information about use of the drugs among children or in particular age ranges. 
Comment
We found that 13.2% of prescriptions for a representative group of children in primary care in Germany were off label. Although we could not detect off label use due to dosage or indication with this database, the proportion of prescriptions that were off label was similar to that in much smaller studies that analysed dosage and diagnoses.
4 5 Our data show that efforts to improve the quality of pharmacotherapy in children should not exclude widely marketed and firmly established drugs.
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4 5 We studied drugs taken by children in the community, based on the pharmacy records of prescriptions from both general practitioners and outpatient departments. We aimed to determine the number of prescriptions for unlicensed drugs for children in the community and to investigate paediatric labelling of all drugs with a product licence to determine the extent of off label use.
Participants, methods, and results
In the Netherlands people commonly register with one pharmacy, from which they obtain their drugs, including those prescribed as outpatients. Excluded are drugs used during hospital stays and those bought over the counter. We obtained our data on dispensing from the InterAction database, which covers part of the northern Netherlands.
We selected all prescriptions for children aged 0-16 years in 2000. Dutch pharmacies are allowed to prepare their own formulations and to modify commercial preparations. These pharmacy based preparations are exempt from licensing, and we classified them as unlicensed. For each prescription of a licensed drug (all remaining prescriptions) we examined the official licence information-the summary of product characteristics-in detail. We determined whether the summary mentioned use in children and, if so, the minimum age. When age was unspecified we set it at a minimum of 0 years. If use in children was not mentioned or was advised against without an indication of age, we set the minimum age at 18 years. We considered that a drug with a product licence was used according to the label if the summary of product characteristics stated that it could be used in children, and if the child was of the minimum age for use or older; otherwise we considered the drug was used off label. As information about indications was not available, we were not able to distinguish between different indications in the summary.
We analysed 68 019 prescriptions for 19 283 children aged 0-16 years. General practitioners were responsible for 56 961 (83.7%) of the prescriptions; the remainder came from specialists. Unlicensed drugs amounted to 16.6% (11 288) of the total pre-
